Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

Gandhi Damaj¹, Ali Bazarbachi², Philipp Berning³, Anne-Ségolène Cottereau⁴, Christopher P Fox⁵, Charalampia Kyriakou⁶, Kate Cwynarski⁶, Pier-Luigi Zinzani⁷, Olivier Tournilhac⁸, Wojiech Jurczak⁹, Imke E Karsten³, Fengrong Wang¹⁰, Ambroise Marcais¹¹, Alina Tanase¹², Stéphanie Nguyen-Quoc¹³, Yasmina Serroukh¹⁴, Mahmoud Aljurf¹⁵, David Beauvais¹⁶, Gerald Wulf¹⁷, Anna Sureda¹⁸, Paolo Corradini¹⁹, Olivier Hermine²⁰, Mehdi Hamadani²¹, Francesco Onida²², Anna Lisa Ruggeri²³, Isabel Sanchez-Ortega²⁴, Ibrahim Yakoub-Agha²⁵, Peter Dreger²⁶, Norbert Schmitz²⁷

Affiliations

¹ Haematology Institute and University of Caen, CRNS, ISTCT UMR6030, GIP Cyceron, Caen, France.
² Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
³ Department of Medicine A, University Hospital Muenster, Muenster, Germany.
⁴ Department of Nuclear Medicine, Paris Cité University, Cochin Hospital, APHP, Paris, France.
⁵ School of Medicine, University of Nottingham, Nottingham, UK.
⁶ Department of Haematology, University College London Hospital, London, UK.
⁷ 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli 2 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
⁸ Department of Haematology and Cell Therapy, Clermont-Ferrand University Hospital, University Clermont Auvergne, Clermont-Ferrand, France.
⁹ Department of Clinical Oncology, Maria Sklodowska Curie National Research Institute of Oncology, Krakow, Poland.
¹⁰ Institute of Haematology, National Clinical Research Centre for Haematologic Disease, Peking University People's Hospital, Peking University, Beijing, China.
¹¹ Service Hématologie Adultes, Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médicale (INSERM) U1151, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France.
¹² Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
¹³ Department of Hematology and Cellular Therapy, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
¹⁴ Department of Haematology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, Netherlands.
¹⁵ Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
¹⁶ Haematology Department, Lille University Hospital, Université Lille, INSERM U1192 PRISM, Lille, France.
¹⁷ Department of Haematology and Medical Oncology, University Hospital Goettingen, Goettingen, Germany.
¹⁸ Clinical Haematology Department, Institut Cataà d'Oncologia-L'Hospitalet, Institut de Recerca Biomèdica de Bellvitge, Universitat de Barcelona, Spain.
¹⁹ Fondazione IRCCS Istituto Nazionale dei Tumori Milano, University of Milano, Milan, Italy.
²⁰ Service Hématologie Adultes, Institut Necker-Enfants Malades, INSERM U1153, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris Cité and Imagine Institute, Paris, France.
²¹ Division of Haematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
²² Haematology and BMT Centre, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.
²³ Haematology and BMT Unit, IRCCS San Raffaele Hospital, Milan, Italy.
²⁴ EBMT Executive Office, Barcelona, Spain.
²⁵ Lille University Hospital, INSERM U1286, Infinite, Lille, France.
²⁶ Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
²⁷ Division of Haematology and Oncology, Department of Medicine A, University Hospital Muenster, Muenster, Germany. Electronic address: norbert.schmitz@ukmuenster.de.

PMID: 40610175
DOI: 10.1016/S2352-3026(25)00073-0

Review

Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

Gandhi Damaj et al. Lancet Haematol. 2025 Jul.

. 2025 Jul;12(7):e542-e554.

doi: 10.1016/S2352-3026(25)00073-0.

Authors

Affiliations

¹ Haematology Institute and University of Caen, CRNS, ISTCT UMR6030, GIP Cyceron, Caen, France.
² Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
³ Department of Medicine A, University Hospital Muenster, Muenster, Germany.
⁴ Department of Nuclear Medicine, Paris Cité University, Cochin Hospital, APHP, Paris, France.
⁵ School of Medicine, University of Nottingham, Nottingham, UK.
⁶ Department of Haematology, University College London Hospital, London, UK.
⁷ 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli 2 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
⁸ Department of Haematology and Cell Therapy, Clermont-Ferrand University Hospital, University Clermont Auvergne, Clermont-Ferrand, France.
⁹ Department of Clinical Oncology, Maria Sklodowska Curie National Research Institute of Oncology, Krakow, Poland.
¹⁰ Institute of Haematology, National Clinical Research Centre for Haematologic Disease, Peking University People's Hospital, Peking University, Beijing, China.
¹¹ Service Hématologie Adultes, Institut Necker Enfants Malades, Institut National de la Santé et de la Recherche Médicale (INSERM) U1151, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France.
¹² Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
¹³ Department of Hematology and Cellular Therapy, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
¹⁴ Department of Haematology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, Netherlands.
¹⁵ Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
¹⁶ Haematology Department, Lille University Hospital, Université Lille, INSERM U1192 PRISM, Lille, France.
¹⁷ Department of Haematology and Medical Oncology, University Hospital Goettingen, Goettingen, Germany.
¹⁸ Clinical Haematology Department, Institut Cataà d'Oncologia-L'Hospitalet, Institut de Recerca Biomèdica de Bellvitge, Universitat de Barcelona, Spain.
¹⁹ Fondazione IRCCS Istituto Nazionale dei Tumori Milano, University of Milano, Milan, Italy.
²⁰ Service Hématologie Adultes, Institut Necker-Enfants Malades, INSERM U1153, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris Cité and Imagine Institute, Paris, France.
²¹ Division of Haematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
²² Haematology and BMT Centre, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.
²³ Haematology and BMT Unit, IRCCS San Raffaele Hospital, Milan, Italy.
²⁴ EBMT Executive Office, Barcelona, Spain.
²⁵ Lille University Hospital, INSERM U1286, Infinite, Lille, France.
²⁶ Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
²⁷ Division of Haematology and Oncology, Department of Medicine A, University Hospital Muenster, Muenster, Germany. Electronic address: norbert.schmitz@ukmuenster.de.

PMID: 40610175
DOI: 10.1016/S2352-3026(25)00073-0

Abstract

Allogeneic haematopoietic cell transplantation (HCT) is a potentially curative therapy for peripheral T-cell lymphoma; however, to date, there are no standardised and detailed guidelines for its application. To address gaps in clinical practice, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonisation and Guidelines Committee convened an international expert meeting in Lille (France) on Sept 30 and Oct 1, 2024. EBMT performed funding acquisition. The chairs invited experts in T-cell lymphoma and HCT, who were organised in two work packages devoted to peripheral T-cell lymphoma and transplantation. A literature search was performed beforehand, and results were presented by subgroups of two or three experts, then discussed collectively in structured discussions, and consensus-building exercises. The recommendations presented in this Review were developed and approved based on current evidence, expert opinion, and clinical experience. These recommendations should help to further establish allogeneic HCT as the standard of care for eligible patients with refractory or relapsed peripheral T-cell lymphoma, leveraging its curative potential through the graft-versus-lymphoma effect.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests GD: honoraria from Takeda and Amgen; travel support from Takeda; research support from Takeda and Ideogen. AB: honoraria from Takeda, Amgen, Janssen, Roche, and Maat Pharma; research support from Takeda, Roche, Novartis and Janssen. A-SC: travel support from Roche. CPF: consultancy for AbbVie, Arvinas, Atarabio, Bristol Myers Squibb (BMS), GenMab, Kite Pharma (Gilead Sciences), Incyte, Eli Lilly, MorphoSys, Ono, Roche, SERB, SOBI, and Takeda; research funding from BeiGene, AbbVie and GenMab, and Incyte. CK: research support from BMS; travel support from Takeda. KC: consulting or advisory role at Roche, Gilead, KITE, Incyte, AbbVie, BMS, Secura Bio, Autolus, and Sobi; speakers’ bureau for Acrotech, Roche, KITE, Gilead, and Incyte; conference and travel support from Roche, Kite Pharma, and BMS. P-LZ: consultancy for MSD, Takeda, Novartis, and Recordati; speakers bureau for Sobi, Kite Pharma (Gilead Sciences), Janssen, BMS, Servier, MSD, AstraZeneca, Takeda, Roche, Recordati, Kyowa Kirin, Novartis, Incyte and BeiGene; advisory board for Sobi, Kite (Gilead Sciences), Janssen, BMS, Servier, MSD, AstraZeneca, Takeda, Roche, Recordati, Kyowa Kirin, Novartis, Incyte, BeiGene Secura Bio, Sandoz, and ADC Therapeutics. OT: honoraria from Takeda and BeiGene; travel support from Takeda, AbbVie, AstraZeneca, and BeiGene; research support from Takeda. WJ: honoraria from Takeda and AbbVie. IEK: supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—493624047 (Clinician Scientist CareerS Muenster); honoraria from Kite (Gilead Sciences); travel grants from BeiGene. SN-Q: honoraria from Jazz Pharma, Novartis, AbbVie, and Gilead Sciences; travel support from AbbVie, Gilead Sciences, Sanofi, and Neovii. DB: honoraria from Kite (Gilead Sciences) and Novartis. GW: honoraria from Takeda, Gilead Sciences, Novartis, and Clinigen; travel support from Medac and Janssen. AS: honoraria from Takeda, Calgene (Bristol-Myers Squib), MSD, Janssen, Amgen, Novartis, Kite (Gilead Sciences), Sanofi, Roche, GenMab, AbbVie, Jazz Pharmaceuticals, Therakos, and Menarini; consultancy for Takeda, Calgene (Bristol-Myers Squib), Novartis, Janssen, Gilead Sciences, Sanofi, GenMab, and AbbVie; speaker's bureau for Takeda; research support from Takeda; non-profit organisations: president of the EBMT. PC: honoraria from Takeda, Gilead Sciences, Novartis, Calgene (Bristol-Myers Squib), Roche, Incyte, and Eli Lilly. MH: research support or funding from ADC Therapeutics, Spectrum Pharmaceuticals, and Astellas Pharma; consultancy for Genmab, CRISPR, Allovir, Caribou, Autolus, Forte Biosciences, and Byondis; speaker's bureau for AstraZeneca, ADC Therapeutics, BeiGene, Kite (Gilead Sciences), and Sobi. FO: honoraria from Takeda, Medac Pharma, and Kyowa Kirin; travel support from Takeda, Jazz Pharma, and Kyowa Kirin. IY-A: honoraria from novartis, Bristol-Meyers Squib, Kite (Gilead Sciences), Janssen, and Pfizer. All other authors declare no competing interests.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

Affiliations

Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources